Data first, trial second: Rethinking evidence generation in rare disease

Published on: Nov 18, 2026

Rare-disease drug development has rarely been constrained by trial design; evidence design is the critical success factor. The current status quo encourages "phase 3 thinking in a phase 0 world." The moment a sponsor has a promising preclinical asset, teams begin debating randomization ratios and endpoints for a pivotal trial that may never be the most important source of evidence.

Instead, we must flip the paradigm. We should not ask, "What should our trial design look like?" We must ask, "What is the integrated evidence package required to convince regulators, payers, physicians, and patients that this treatment meaningfully changes lives?" In this new model, the clinical trial is just one piece of a broader data collection strategy.
 

Continue reading

 

Return to Insights Center

Related Insights

Blog

FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research

Oct 29, 2026

Article

A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?

Oct 26, 2026

Article

China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies

Oct 22, 2026

Webinar

The evidence gap in hematology: From trial endpoints to patient outcomes

Oct 1, 2026

Case Study

Speed meets strategy: Delivering a critical FDA 1572 package in just seven days

Sep 9, 2026

Blog

Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts

Aug 19, 2026

Blog

Japan: the new strategic launchpad for accelerating global rare disease development

Jul 23, 2026

Blog

A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting

Jun 23, 2026

Blog

Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think

Jun 23, 2026

Blog

Faster access for rare disease patients starts with smarter alignment

Jun 22, 2026

CTB Blog

Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies

Mar 5, 2026

Blog

Bolster your investor narrative with RWE

Jan 26, 2026

Related Insights

Blog

FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research

Oct 29, 2026

Article

A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?

Oct 26, 2026

Article

China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies

Oct 22, 2026

Webinar

The evidence gap in hematology: From trial endpoints to patient outcomes

Oct 1, 2026

Case Study

Speed meets strategy: Delivering a critical FDA 1572 package in just seven days

Sep 9, 2026

Blog

Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts

Aug 19, 2026

Show more